Scalper1 News
Big-cap biotech BioMarin Pharmaceuticals (BMRN) got a host of price target increases and hit a new high in early trading Thursday after it reported success in a trial of a dwarfism drug late Wednesday. BioMarin said its drug vosoritide, or BMN-111, had yielded a 50% improvement in annual growth velocity in a phase-two study of children with achondroplasia, the most common form of dwarfism. No serious adverse events were reported. The company will Scalper1 News
Scalper1 News